HALEON’S RE-RATING IS ONE LEG SHORT (BUY; 33% UPSIDE)
14/09/26 -" Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled from the GSK, Novartis and Pfizer consumer arms, the ..."
Pages
56
Language
English
Published on
14/09/26
You may also be interested by these reports :
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
08/09/26
Bic’s 2030 strategy is credible and modestly positive for earnings and cash flow, with c.3% organic growth and >15.5% EBIT margin targets above the ...
08/09/26
BIC’s new 2030 strategy looks positive for earnings and cash generation, with growth, margin and capex targets ahead of the current consensus. The ...
26/08/26
Since our initiation of coverage in December 2024, we have maintained our optimistic view on Puig (BUY; Spain). Our initial positive stance was ...